Related Posts
-
Evidentiary Considerations for Integration of Biomarkers in Drug Development Symposium -
Dr. Brumfield’s Remarks at Partnering for Cures -
Dr. Janet Woodcock, Director, Center for Drug Evaluation and Research, on FDA’s Critical Path Initiative
-
Brian Harvey, VP, U.S. Regulatory Policy at Sanofi, speaks on panel at Partnering for Cures Nov. 8, 2011